Preview Mode Links will not work in preview mode

Oncology Overdrive

Sep 9, 2021

In this episode, Lance Baldo, MD, discusses the use of MRD testing, T-cell receptor profiling, and how lessons from the COVID-19 pandemic will help shape the future of cancer vaccines.

  • Welcome to another exciting episode of Oncology Overdrive :13
  • About Baldo :17
  • The interview 1:20
  • Tell me about your journey 1:38
  • Did you question your decision to leave clinical practice for an entrepreneurial venture? 2:36
  • What does Adaptive Biotechnologies do? 3:43
  • What is Minimal Residual Disease (MRD) testing and how is it used? 4:27
  • Are you looking only at hematologic malignancies? 5:35
  • How are experts using MRD testing in clinical practice? 6:31
  • Why do you think MRD testing is important in treating cancers? 7:24
  • Is Adaptive working on drug discovery and development related to MRD testing? 9:20
  • Personalized care and how real life feels like science fiction 12:02
  • Doing what’s best for the patient 15:33
  • Tell me about T-cell receptor profiling 18:02
  • Tell me about neo-antigen-based therapy 21:10
  • Are these types of technologies available outside of large, academic institutions? 22:49
  • Has COVID impacted the way you and your team think about implementing therapies and innovation? 25:03
  • Do you think what we’ve learned over the last year will help with the creation of future cancer vaccines? 29:59
  • If we spoke again in 10 years, what would you hope to have done? 31:25
  • Baldo’s take-home message 37:42
  • Where to find Baldo 38:57

Lance Baldo, MD, is chief medical officer of Adaptive Biotechnologies.

We’d love to hear from you! Send your comments/questions to Dr. Jain at Follow us on Twitter @HemOncToday and @ShikhaJainMD. Baldo can be reached on LinkedIn, via email at and at   

Disclosures: Baldo is chief medical officer of Adaptive Biotechnologies. Jain reports she is a paid freelance writer for Lippincott.